LIFETECH SCI (01302) announced its interim results for 2025, reporting revenue of approximately RMB 677 million, representing a year-on-year increase of about 3.7%. Gross profit reached approximately RMB 498 million, declining by about 3.4% compared to the same period last year. Profit attributable to owners amounted to RMB 55.074 million, down 73.21% year-on-year, with earnings per share of 1.3 cents.

According to the announcement, the revenue growth was primarily driven by increased sales of covered stents and left atrial appendage occluders. The gross margin for the first half of 2025 decreased by 5.3 percentage points year-on-year to approximately 73.6%, mainly due to reduced selling prices for certain products in specific regions affected by volume-based procurement policies, as well as changes in sales mix.

The decline in net profit was primarily attributed to changes in non-recurring items.